Benjamin F. Edwards & Company Inc. Has $2.56 Million Position in Danaher Co. (NYSE:DHR)

Benjamin F. Edwards & Company Inc. grew its holdings in Danaher Co. (NYSE:DHR) by 14.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,260 shares of the conglomerate’s stock after purchasing an additional 1,321 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in Danaher were worth $2,563,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Cape Investment Advisory Inc. acquired a new stake in Danaher during the fourth quarter worth about $25,000. Tsfg LLC grew its position in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new stake in Danaher during the second quarter worth about $25,000. nVerses Capital LLC acquired a new stake in Danaher during the second quarter valued at approximately $25,000. Finally, Redmont Wealth Advisors LLC acquired a new stake in Danaher during the first quarter valued at approximately $30,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 over the last ninety days. Insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of NYSE:DHR opened at $272.63 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The stock has a market capitalization of $201.93 billion, a P/E ratio of 46.21, a P/E/G ratio of 4.48 and a beta of 0.83. The business has a 50-day moving average price of $267.62 and a two-hundred day moving average price of $257.16.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. Danaher’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.05 earnings per share. Equities analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is 18.31%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Robert W. Baird lifted their price objective on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Wells Fargo & Company assumed coverage on Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective on the stock. TD Cowen lifted their price objective on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Stifel Nicolaus lifted their price objective on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Finally, The Goldman Sachs Group lifted their price objective on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.